All In Biotech

Drug Trial Radar · NCT07213765

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Sep 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Bin CaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MicuRx; Shanghai Pulmonary Hospital, Shanghai, China; Beijing Chest Hospital; Anhui Chest Hospital; Jiangxi Chest Hospital; Guangzhou Chest Hospital.; Weifang Second People's Hospital; Shandong Public Health Clinical Center; Changsha Central Hospital
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease? What medical problems do participants have when taking contezolid for an extended length? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease? Participants will: Take contezolid and standard regimen (azithromycin, ethambutol, and rifampicin) for 6 months, contezolid is administered every day while other drugs are taken three times a week OR take standard regimen three times a week for 12 months. Visit the clinic once every 1 month for checkups and tests.

Conditions

  • Mycobacterium Avium Complex Pulmonary Disease

Interventions

  • ContezolidDrug

    contezolid 800mg po q12h\*6m

  • AzithromycinDrug

    azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*6m

  • AzithromycinDrug

    azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*12m

  • Ethambutol (E)Drug

    ethambutol 25mg/kg po tiw\*6m

  • Ethambutol (E)Drug

    ethambutol 25mg/kg po tiw\*12m

  • Rifampicin (R)Drug

    rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*6m

  • Rifampicin (R)Drug

    rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*12m

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. culture conversionTime frame: end of month 6
  2. CT lesion absorptionTime frame: end of month 6
  3. QOL-B+NTM moduleTime frame: end of month 6

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Chest Hospital

    Hefei, Anhui, China · Recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou Chest Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Jiangxi Chest Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.